At the Scleroderma Research Foundation, research is at the center of all we do.

What is CONQUER?

In 2018, The SRF launched the CONQUER Registry (an acronym for COllaborative National Quality and Efficacy Registry) – a first-of-it’s-kind nationwide patient registry and biosample repository aimed at improving care and developing more effective, personalized therapies for systemic sclerosis (scleroderma) patients.

CONQUER was created through a collaborative effort among the largest scleroderma centers in the U.S. With the goal of enrolling thousands of patients from around the country, researchers and clinicians will be able to learn as much as possible about all forms of scleroderma in patients of all backgrounds and ethnicities, and use that knowledge to advance research and discovery.

How It Works

  • Patients participate through their routine clinical visits (2x/year), contributing Clinical data & Blood samples
  • Patients also contribute data through Patient-Reported Outcome surveys. (This can be done at the patient’s convenience.)
  • Enrolled Patients receive the most modern standard of care. There are no experimental therapies involved in CONQUER.

Who is Eligible?

To be eligible for CONQUER you must:

  • Be 18 years of age or older
  • Have systemic scleroderma
  • Be within first 5 years of first non-Raynaud’s symptom (Enrollment is time sensitive)
  • You can participate in CONQUER even if you are enrolled in another registry.

CONQUER will benefit every scleroderma patient, even those unable to enroll.

How Do I Participate?

  • The 13 institutions listed below are the sites participating in the CONQUER REGISTRY Project.
  • We do anticipate that other expert sites will be added over time and are in the process of evaluating such additions now. If you are a patient at one of these participating centers, ask your doctor about enrolling in CONQUER.
  • Otherwise, please contact the Scleroderma Research Foundation at
Institution Principal Investigator Contact Information
Columbia University Elana Bernstein, MD, MSc
George Washington University Victoria Shanmugam, MD 202-741-2488
Georgetown University Virginia Steen, MD
Hospital for Special Surgery Jessica Gordon, MD
Johns Hopkins University Ami Shah, MD Laura Hummers, MD 410-550-7715
Mass General Hospital Flavia Castelino, MD
Medical University of South Carolina Faye Hant, DO, MSCR 843-792-1991
Northwestern University Chase Correia, MD
Stanford University Lori Chung, MD, MS
University of Michigan Dinesh Khanna, MD
University of Pennsylvania Nora Sandorfi, MD 215-614-4430
The University of Texas Health Science Center at Houston Shervin Assassi, MD 713-486-3100
University of Utah Tracy Frech, MD 801-585-6468

Learn About CONQUER

Watch an informative webinar explaining the importance of the CONQUER Registry and how it could lead to finding a cure.

Watch the Webinar

How Does My Data Get Used and is it Protected?

  • Your clinical data and blood samples will be de-identified so no one can get personal information about you.
  • CONQUER data is protected in a secure data center at the University of Utah. This Data Coordinating Center specializes in the storage & analysis of large-scale clinical studies.
  • CONQUER blood samples are stored separately at the University of Texas-Houston – the largest biorepository of scleroderma samples in the world

What is the Benefit to Me?

  • Your participation will help accelerate advances in clinical care
  • This registry supports the development of new therapies​
  • Patients enrolled in CONQUER will experience heightened scrutiny and care in a formal setting
  • In the future, CONQUER will include a clinical trials platform for rapid testing of new drugs and enrolled patients may be eligible to participate in these trials​.

Still Want More Information About Conquer?

CONQUER Newsletters

  • January 2021
  • December 2020
  • November 2020

Dive Deeper into Our Research

Dig into the details of our research program to understand more about the science behind what our elite researchers are doing to find better treatments and, ultimately, a cure.

Learn More